ACROBiosystems Inc.

05/21/2026

Why everyone loves the Baby Llama:
✅ Pocket-sized companion
✅ Cute desk buddy

Our May campaign is ending soon, but there's still time to join and receive an exclusive Baby Llama Keychain with your order.

Don't miss out: https://www.acrobiosystems.com/activities/promotions/5764?utm_source=facebook&utm_medium=social&utm_campaign=4444Cn165&utm_content=32845&utm_term=0521

05/20/2026

[ACRO Event - US]

has officially come to a close, and we were pleased to present our talk, A Platform for Validating LNP Targeting Efficiency Using Fluorescent-labeled Proteins and Antibodies.

It was exciting to see a full room, and we sincerely thank everyone who joined the session and contributed thoughtful questions. Your interest and engagement made the discussion especially meaningful.

If you would like to continue the conversation or learn more about the products featured in the presentation, please feel free to connect with our presenter, Hui Yu, Field Application Development Director.

We are honored to have been part of this year’s meeting and look forward to staying connected with the community as we continue supporting progress in cell and gene therapy through reliable solutions and meaningful collaboration.

05/13/2026

May can get busy —
so maybe it’s time for a little company. 🦙🦙

Already have one of our plushie llamas?
🦙 Now’s the perfect time to bring home a second companion.

Don’t have one yet?
🦙 Place an order in May and let a baby llama keep you company through long lab days, meetings, and everyday moments.

Click to learn more: https://www.acrobiosystems.com/activities/promotions/5764?utm_source=facebook&utm_medium=social&utm_campaign=4444Cn165&utm_content=32845&utm_term=0513

05/12/2026

For years, iPSC reprogramming has faced a difficult trade-off: higher efficiency often came at the cost of genomic stability, frequently involving p53 suppression.

A new study published in Cell Press by Deng Hongkui’s team at Peking University challenges this long-standing view. In chemical reprogramming (CiPSC), which avoids exogenous genes, p53 was shown to act not as a barrier, but as a key safeguard for both cell fate fidelity and genome integrity — a major conceptual shift for stem cell biology and regenerative medicine (Read the paper: DOI: 10.1016/j.cell.2026.03.038).

In this work, Fibronectin from ACROBiosystems supported cell adhesion and viability during early-stage reprogramming, helping establish a reliable starting environment.

Beyond Fibronectin, we offer a broad portfolio of RG, PG, and GMP-grade ECM proteins — including Laminin 521, Laminin 511, and Vitronectin — supporting iPSC/MSC culture and multiple clinical-stage cell therapy programs spanning T/NK cells, pancreatic islets, neural cells, cardiomyocytes, and RPE differentiation.

Explore our ECM portfolio: https://www.acrobiosystems.com/category/cell-culture-reagents/ecm-proteins?utm_source=facebook&utm_medium=social&utm_campaign=4363Cg115&utm_content=TGJXEN32884&utm_term=0512

05/06/2026

May can get busy —
so we made something small to keep you company.

Our baby llama keychain - a tiny companion for your everyday moments. 🦙

👉Claim your little buddy here: https://www.acrobiosystems.com/activities/promotions/5764?utm_source=facebook&utm_medium=social&utm_campaign=4444Cn165&utm_content=32845&utm_term=0506

04/30/2026

[Live Webinar] Cell-Based Platforms Driving the Next Wave of Drug Development

📅 Date: May 12, 2026
🕙Time: 10 AM PT | 1 PM ET | 5 PM GMT | 7 PM CET

As drug discovery evolves, screening efficiency is critical to R&D success. Traditional methods often fall short when addressing complex targets and high-throughput demands. In this webinar, we'll explore how cell-based platforms are transforming early-stage drug development.

💡 Key Highlights:
- How functional cell lines enhance screening efficiency and reliability
- Key applications in target validation and drug screening
- Insights into cell model selection and assay development
- Strategies to streamline workflows and accelerate R&D

Reserve your seat: https://event.on24.com/wcc/r/5316790/82132B6B80D7BF27CCAE7F864B98F232?partnerref=facebook

Tuesday, May 12, 2026 at 10:00 AM Pacific Daylight Time. Drug discovery is increasingly defined by the need for faster, more precise screening. Traditional methods often fall short when faced with complex targets and high-throughput demands. Functional cell lines offer a powerful alternative—combi...

04/28/2026

Last Call: Easter Campaign Ending Soon 🐣

Our Easter campaign is coming to an end soon — this is your final chance to join in!

Don’t miss the opportunity to receive our limited-edition Easter cup and exclusive stickers 🐰🎁

👉 Join now & claim your Easter gift: https://www.acrobiosystems.com/activities/promotions/5758?utm_source=facebook&utm_medium=social&utm_campaign=4275Cn165&utm_content=TGJXEN31828&utm_term=0428

04/22/2026

🧬
iPSC-based regenerative medicine starts with one critical step: matrix coating.The extracellular matrix isn’t just a scaffold. It directs cell adhesion, survival, and differentiation fate.

🔬 Three key matrix proteins for iPSC culture:
1️⃣Laminin
2️⃣Vitronectin
3️⃣Fibronectin
Choosing the right matrix = higher reproducibility + safer cell therapy products.

We launch Research Grade, Premium Grade and GMP Grade Laminin, Fibronectin, Vitronectin and other ECM proteins. They provide an optimal microenvironment for hPSCs, supporting R&D to clinical translation.
Which matrix do you rely on for your iPSC workflow? Let’s discuss below 👇

Explore Our Products Now: https://www.acrobiosystems.com/category/cell-culture-reagents/ecm-proteins?utm_source=facebook&utm_medium=social&utm_campaign=4363Cg115&utm_content=TGJXEN32710&utm_term=ipscmonth

04/14/2026

Travel with . Celebrate with . 🐰✨

This Easter season, we’re embracing the spirit of connection, innovation, and discovery.

As you continue advancing your research, we’re pleased to share a small token of appreciation—our limited-edition ACRO Easter gifts, including an exclusive mug and themed stickers.

A simple way to celebrate the great view together, while supporting your work with trusted solutions.

👉 Discover more and enjoy Easter with ACRO: https://www.acrobiosystems.com/activities/promotions/5758?utm_source=facebook&utm_medium=social&utm_campaign=4275Cn165&utm_content=TGJXEN31828&utm_term=0414

11/27/2024

[Featured Product]

🔬 CD3 T-Cell Engagers: Transforming Autoimmune Disease Treatment

CD3 T-cell engagers are revolutionizing autoimmune disease therapy by precisely targeting T and B cell antigens. They enable enhanced B cell depletion and provide long-term immune regulation, opening doors to transformative treatments.

At ACROBiosystems, we offer highly active CD3 protein products designed to support:
✔️ Antibody development
✔️ Screening
✔️ Quality control
✔️ Clinical pharmacokinetics

Our solutions accelerate the advancement of bispecific and multispecific antibody therapies, driving innovation in autoimmune treatment.
➡️ Learn More About Our CD3 Products: https://smpl.is/9wjvd

11/26/2024

[Featured Product]

🌟 IL-31: A Key Target in Dermatitis Drug Development

The FDA’s recent approval of nemolizumab, the first IL-31 receptor antibody for adult prurigo nodularis, highlights the pivotal role of IL-31 in treating inflammatory skin diseases. IL-31 drives itch-related neuron activation, inflammation, and skin barrier damage, making it a prime therapeutic target.

At ACROBiosystems, we offer high-quality IL-31/IL-31RA proteins with verified bioactivity to support antibody drug discovery and quality control efforts, advancing innovation in dermatitis treatments.

➡️ Learn more here: https://smpl.is/9wcea